Article 1: Antidote to drugs
Why in news: A counterfeit medicine racket in Bengaluru exposed fake, relabelled and expired drugs, including critical cancer medicines and ICU injections, highlighting serious gaps in India’s pharmaceutical supply-chain regulation.
Key Details
- Counterfeit network: Fake, relabelled and expired medicines were reportedly supplied to 90+ hospitals and clinics across Karnataka.
- Modus operandi: An unlicensed facility near Bidadi was allegedly used to repackage medicines, alter expiry dates and imitate costly imported brands.
- Patient safety: Counterfeit medicines can cause treatment failure, adverse reactions, disability and death, particularly when used for critical conditions.
- Regulatory gaps: The case highlights weaknesses in drug testing, supply-chain monitoring, traceability and enforcement and possible inter-State linkages.
- India needs stronger quality testing, digital traceability, regulatory coordination and strict enforcement to support its ambition of becoming the “pharmacy of the world.”
Counterfeit Drug Racket in Bengaluru
- A recent investigation in Bengaluru uncovered a major counterfeit medicine network supplying fake, relabelled and expired drugs.
- The medicines included cancer drugs and ICU injections, which are critical for time-sensitive medical treatment.
- The network reportedly supplied medicines to more than 90 hospitals and clinics across Karnataka.
Modus Operandi of the Racket
- An unlicensed facility near Bidadi was found storing suspected fake and expired medicines.
- Drugs were reportedly repacked, given altered expiry dates and falsely presented as expensive imported brands.
- The medicines were then sold at large discounts, with the seized consignment having a label value of around ₹5 crore.
Patient Safety Concerns
- The most serious concern is the potential impact on patient safety, particularly where critical medicines are involved.
- Fake or expired drugs can cause adverse reactions, treatment failure, severe disability and even death.
- The case also raises questions about possible collusion within private hospital and pharmacy networks.
Gaps in Drug Regulation
- The incident highlights weaknesses in drug-quality monitoring, supply-chain scrutiny and enforcement mechanisms.
- Investigators are examining possible inter-State links and reviewing the complete medicine supply chain.
- The recurring discovery of substandard and counterfeit medicines shows the need for stronger regulatory oversight and quality-control systems.
India’s ‘Pharmacy of the World’ Ambition
- India seeks to become the “pharmacy of the world”, but this requires consistently high standards for medicines manufactured and distributed domestically.
- Recent cases involving contaminated cough syrups and counterfeit medicines have raised concerns about the credibility of India’s pharmaceutical supply chain.
- Stronger testing, traceability, enforcement and quality assurance are essential to protect patients and strengthen confidence in Indian-made medicines.
Conclusion
Counterfeit medicines are not merely a regulatory violation but a serious public-health threat. India’s pharmaceutical ambitions require robust quality assurance across manufacturing, distribution and retail. Strengthening drug-testing capacity, supply-chain traceability, inter-State coordination, inspections and penalties can reduce counterfeit circulation. Greater accountability of hospitals, pharmacies and distributors is equally important to ensure safe medicines and maintain global confidence in Indian pharmaceuticals.
Descriptive question:
Counterfeit medicines pose a serious challenge to public health and India’s pharmaceutical credibility. Examine the regulatory gaps and suggest measures to strengthen drug quality and supply-chain integrity. (150 words, 10 marks)